Rhythm Pharmaceuticals, Inc. (RYTM) Balance Sheet

The balance sheet is weakening despite a 45.8% YoY revenue surge, as retained earnings deepened to -$1.5B. Total assets contracted 9% from Q4 2025 to Q2 2026, driven by cash consumption and a reduction in other assets, while liabilities rose modestly. This suggests the company is still in a heavy investment phase, with equity increasingly dependent on external financing rather than organic profitability.

The company carries negligible debt, indicating no immediate refinancing risk, but this also reflects a lack of access to cheap debt given its negative profitability. The low leverage is a double-edged sword: it provides balance sheet flexibility, yet the high cash burn rate suggests that equity dilution is the likely funding path. Investors should monitor whether management can secure non-dilutive partnerships or if a capital raise becomes necessary.

The company's asset mix is typical of a commercial-stage biotech: low PPE (0.7% of total assets) and modest goodwill (1.1%), indicating an asset-light model reliant on intellectual property and commercial infrastructure. The gradual decline in goodwill from $6.8M in Q1 2024 to $4.9M suggests amortization or impairment, but the amounts are immaterial. The real asset is the commercial platform and pipeline, which are not captured on the balance sheet.

Equity quality is strained as retained earnings continue to deteriorate, and the reliance on SBC to attract talent is diluting existing shareholders. The equity base is being propped up by capital raises, as evidenced by the jump from $61.6M in Q1 2024 to $217.3M in Q2 2026, but the pace of loss generation suggests future dilution is likely. The high SBC relative to revenue also inflates reported losses, masking the underlying cash burn.

The current ratio of 3.45 appears healthy, but the quick erosion of cash—down 52% YoY—highlights a liquidity crunch. With no debt and minimal capex, the primary cash outflow is operating losses, which are not yet offset by revenue growth. The company may need to raise capital within the next two quarters to sustain operations, unless the HO launch accelerates revenue beyond current expectations.